Theravance Biopharma TBPH Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $17.7M-61.4% | $45.89M+130% | $19.99M-23.7% | $26.2M+70.2% | $15.39M-17.9% | ||
| $5.83M-20.8% | $7.36M-9.3% | $8.11M-22.7% | $10.49M-8.4% | $11.45M+21.1% | ||
| $17.72M-4.3% | $18.52M+1.0% | $18.33M-0.5% | $18.43M+0.3% | $18.37M-0.7% | ||
| $27.18M+5.0% | $25.88M-2.1% | $26.45M-8.6% | $28.92M-3.0% | $29.82M+6.7% | ||
| -$9.48M-147% | $20.01M+410% | -$6.46M-137% | -$2.73M+81.1% | -$14.43M-56.9% | ||
| -53.6%-97.2pp | 43.6%+75.9pp | -32.3%-21.9pp | -10.4%+83.4pp | -93.8%-44.7pp | ||
| —— | $582K+1.6% | $573K-13.6% | $663K+3.1% | $643K0.0% | ||
| $3.01M-17.2% | $3.64M-12.1% | $4.14M+184% | $1.46M+55.2% | $939K+3.9% | ||
| -$6.47M-109% | $73.07M+2,629% | -$2.89M-104% | $73.21M+618% | -$14.14M-58.2% | ||
| -$1.54M-113% | $12.04M+285% | -$6.5M-135% | $18.37M+3,386% | -$559K-108% | ||
| -$4.93M-108% | $61.02M+1,588% | $3.62M-93.4% | $54.84M+504% | -$13.58M+12.5% | ||
| -27.9%-161pp | 133%+115pp | 18.1%-191pp | 209.3%+298pp | -88.2%-5.5pp | ||
| -$0.10-109% | $1.15+1,543% | $0.07-93.5% | $1.08+500% | -$0.27+12.9% | ||
| -$9.1M-145% | $20.41M+437% | -$6.05M-161% | -$2.32M+83.5% | -$14.02M-59.7% | ||
| -51.4%-95.9pp | 44.5%+74.7pp | -30.3%-21.4pp | -8.8%+82.3pp | -91.1%-44.3pp | ||
| -$9.48M-147% | $20.01M+410% | -$6.46M-137% | -$2.73M+81.1% | -$14.43M-56.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Theravance Biopharma's revenue?
- Theravance Biopharma (TBPH) generated $109.8M in revenue over the trailing twelve months, up 68.2% year over year.
- Is Theravance Biopharma profitable?
- Theravance Biopharma reported $114.5M in net income over the trailing twelve months, a 104.3% net margin.
- What are Theravance Biopharma's profit margins?
- Gross margin is 60.8% and operating margin is 1.2%, with a 104.3% net margin.
- What is Theravance Biopharma's earnings per share?
- Theravance Biopharma's diluted EPS over the trailing twelve months is $2.20.
- Where does Theravance Biopharma's income statement data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
